Humacyte’s (HUMA) “Buy” Rating Reiterated at HC Wainwright

Humacyte (NASDAQ:HUMA)‘s stock had its “buy” rating reaffirmed by equities research analysts at HC Wainwright in a report issued on Friday,Benzinga reports. They currently have a $15.00 target price on the stock, up from their previous target price of $12.00. HC Wainwright’s price objective suggests a potential upside of 333.53% from the company’s current price.

Other analysts have also recently issued research reports about the company. D. Boral Capital reaffirmed a “buy” rating and issued a $25.00 price target on shares of Humacyte in a research report on Thursday, November 21st. Benchmark restated a “buy” rating and issued a $15.00 target price on shares of Humacyte in a report on Thursday, October 10th. EF Hutton Acquisition Co. I upgraded Humacyte to a “strong-buy” rating in a report on Monday, September 9th. TD Cowen reissued a “buy” rating and issued a $10.00 price target on shares of Humacyte in a research report on Friday, October 18th. Finally, BTIG Research reaffirmed a “buy” rating and set a $10.00 price objective on shares of Humacyte in a report on Friday, October 18th. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $13.43.

Humacyte Stock Performance

Shares of HUMA opened at $3.46 on Friday. The company has a quick ratio of 1.10, a current ratio of 1.10 and a debt-to-equity ratio of 0.61. Humacyte has a 12 month low of $2.48 and a 12 month high of $9.97. The company’s fifty day moving average is $4.85 and its 200-day moving average is $5.87. The firm has a market cap of $435.47 million, a price-to-earnings ratio of -2.58 and a beta of 1.38.

Insider Buying and Selling

In related news, CEO Laura E. Niklason sold 261,369 shares of the firm’s stock in a transaction that occurred on Wednesday, November 20th. The stock was sold at an average price of $4.40, for a total transaction of $1,150,023.60. Following the completion of the transaction, the chief executive officer now owns 1,730,884 shares in the company, valued at $7,615,889.60. This trade represents a 13.12 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Brady W. Dougan sold 427,459 shares of the company’s stock in a transaction on Tuesday, November 19th. The shares were sold at an average price of $4.34, for a total value of $1,855,172.06. Following the completion of the sale, the director now owns 1,992,253 shares in the company, valued at $8,646,378.02. This trade represents a 17.67 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 1,500,000 shares of company stock valued at $6,606,799 over the last three months. 11.20% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Humacyte

Several institutional investors and hedge funds have recently made changes to their positions in HUMA. Endowment Wealth Management Inc. grew its stake in Humacyte by 3.1% during the second quarter. Endowment Wealth Management Inc. now owns 100,518 shares of the company’s stock worth $482,000 after buying an additional 3,000 shares during the last quarter. nVerses Capital LLC acquired a new position in Humacyte in the second quarter worth $28,000. Private Advisor Group LLC grew its holdings in shares of Humacyte by 1.8% during the third quarter. Private Advisor Group LLC now owns 373,110 shares of the company’s stock worth $2,030,000 after purchasing an additional 6,510 shares during the last quarter. The Manufacturers Life Insurance Company increased its stake in shares of Humacyte by 32.5% in the second quarter. The Manufacturers Life Insurance Company now owns 34,919 shares of the company’s stock valued at $168,000 after buying an additional 8,557 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. raised its holdings in shares of Humacyte by 64.1% in the third quarter. China Universal Asset Management Co. Ltd. now owns 22,955 shares of the company’s stock valued at $125,000 after buying an additional 8,965 shares during the last quarter. Institutional investors and hedge funds own 44.71% of the company’s stock.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.